Navigation Links
ANTIGEN in Biological Technology

PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants

... - a second generation recombinant protective antigen (rPA) anthrax vaccine Third ... RypVax(TM) - a recombinant dual antigen vaccine for plague For more ... Proposals for an Anthrax Recombinant Protective antigen (rPA) Vaccine for the Strategic National ...

Abbott HIV Test Demonstrates Earlier Disease Detection

... immunoassay test designed to detect HIV p24 antigen and antibodies to HIV type 1 (HIV-1 Group M and ... ARCHITECT HIV Combo (Ag/Ab) incorporates HIV p24 antigen detection which enables laboratories to diagnose ... before HIV antibodies are detectable. HIV p24 antigen is a viral protein of the HIV antigen. ...

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

... infection at the cellular level. After protective antigen and the anthrax toxins are produced by the bacteria, protective antigen binds to the anthrax toxin receptor on cell ... Raxibacumab blocks the binding of protective antigen to cell surfaces and prevents the anthrax toxins ...

Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial

... use of dendritic cell therapy using the oncofetal antigen ("OFA"), or iLRP -- immature Laminin Receptor Protein, as a cancer antigen (a protein found on cancer cells that can be ... normal, healthy tissue. QI believes that the OFA antigen can serve as a unique, valuable and ...

PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review

... next generation recombinant protective antigen (rPA) anthrax vaccine. In response to ... - a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation ... agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more ...

Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax

... infection at the cellular level. After protective antigen and the anthrax toxins are produced by the bacteria, protective antigen binds to the anthrax toxin receptor on cell ... Raxibacumab blocks the binding of protective antigen to cell surfaces and prevents the anthrax toxins ...

CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses

... individually or together, are expected to induce antigen specific immune response(s) which, based on other ... to induce and elicit protective immunity and antigen specific antibody production in animal models. ... constructs are chimeric peptides which combine antigen specificity with immune response modulation. ...

CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology

... its proprietary L.E.A.P.S.(TM) (Ligand Epitope antigen Presentation System) vaccine technology. The ... to induce and elicit protective immunity and antigen specific antibody production in animal models. ... constructs are chimeric peptides which combine antigen specificity with immune response modulation. ...

PharmAthene Reports First Quarter 2009 Financial and Operational Results

... - a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation ... agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more ... Proposals for an Anthrax Recombinant Protective antigen (rPA) Vaccine for the Strategic National ...

Medicago succesfully expresses VLP antigen for A H1N1 strain

... that it has successfully expressed a new VLP antigen ("H1 VLP") from the influenza A (H1N1) strain ... in North America and other countries. The antigen was expressed within 14 days of receiving the DNA ... They demonstrate that we can rapidly express an antigen from a new influenza strain without modifying our ...

Dendreon Reports First Quarter 2009 Financial Results

... the study also indicate that CD54 upregulation on antigen Presenting Cells (APC), a measure of product ... prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of ... The Company applies its expertise in antigen identification, engineering and cell processing ...

CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies

... its proprietary L.E.A.P.S.(TM) (Ligand Epitope antigen Presentation System) vaccine technology could ... to induce and elicit protective immunity and antigen specific antibody production in animal models. In ... constructs are chimeric peptides which combine antigen specificity with immune response modulation. ...

PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research

... a novel second generation recombinant protective antigen (rPA) anthrax vaccine that is being developed for ... with good immunologic memory demonstrated after antigen exposure at 6 or 12 months. "This is an ... - a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation ...

CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease

... utilizing its L.E.A.P.S.(TM) (Ligand Epitope antigen Presentation System) vaccine technology can ... to vaccinations. It also has application for antigen sparing (reducing the amount/dose of antigen required for protective immunity), and to ...

Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer

... the study also indicate that CD54 upregulation on antigen Presenting Cells (APCs), a measure of potency, is ... prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of ... prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of ...

PharmAthene Announces $5.5 Million Public Equity Offering

... - a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation ... agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more ... Proposals for an Anthrax Recombinant Protective antigen (rPA) Vaccine for the Strategic National ...

PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting

... a novel second generation recombinant protective antigen (rPA) anthrax vaccine that is being developed for ... protein component known as the anthrax Protective antigen (PA) of the lethal toxin complex produced by the ... - a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation ...

Pharmathene Reports Third Quarter 2008 Financial and Operational Results

... - a second generation recombinant protective antigen (rPA) anthrax vaccine -- Valortim(R) - a ... agents -- RypVax(TM) - a recombinant dual antigen vaccine for plague -- a third generation rPA ... Proposals for an Anthrax Recombinant Protective antigen (rPA) Vaccine for the Strategic National ...

Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)

... collected to assess bacteremia and protective antigen in blood. Samples were analyzed for protective ... protein component known as the anthrax protective antigen (PA) of the lethal toxin complex produced by the bacterium. The anthrax protective antigen is believed to initiate the onset of the illness ...

PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program

... of a third generation recombinant protective antigen (rPA) anthrax vaccine. The objective of the ... and produces three toxins. Anthrax Protective antigen (PA) initiates the onset of the illness by ... - a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation ...

PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration

... Company's proposal for its recombinant protective antigen anthrax vaccine, SparVax(TM), has completed a ... Proposals for an Anthrax Recombinant Protective antigen (rPA) Vaccine for the Strategic National ... - a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation ...

Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development

... IRVINE, Calif., July 3 /PRNewswire/ -- antigen Discovery Inc. ("ADI", formerly ImmPORT ... therapeutics, is the continued lack of effective antigen and biomarker discovery tools," said Dr. Xiaowu ... different stages of the same infection." About antigen Discovery Inc. ...

Dendreon Reports First Quarter 2008 Financial Results

... $0.08 per share associated with commercial antigen purchases. Cash, cash equivalents, short-term, ... Immunotherapy, which is based on the same antigen Delivery Cassette(TM) technology as PROVENGE, ... cancer. The Company applies its expertise in antigen identification, engineering and cell processing ...

U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile

... Services (HHS) has accepted H5N1 bulk vaccine antigen to produce approximately 38.5 million doses of ... vaccine. The dose calculation is based on antigen concentration of seasonal influenza vaccine, ... which contains 90 mcg per dose, bulk antigen will yield 6.4 million doses. Since the vaccine ...

PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit

... now includes: -- A recombinant Protective antigen (rPA) anthrax vaccine -- A recombinant dual antigen Plague vaccine manufactured in E coli -- A third ... Proposals) for an Anthrax Recombinant Protective antigen (rPA) Vaccine for the Strategic ...

PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia

... a second generation recombinant Protective antigen (rPA) anthrax vaccine, a recombinant dual antigen plague vaccine, and a third generation rPA ... will include: -- a recombinant Protective antigen (rPA) anthrax vaccine -- Valortim(TM), a fully ...

Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation

... manuscript titled, "CD54 is a surrogate marker of antigen presenting cell activation" in Cancer Immunology, ... supports the use of CD54 as a surrogate marker of antigen presenting cell activation (APC) activation and ... CD54 and the upregulation of its expression on antigen presenting cells (APC) as a means by which human ...

GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicology Studies

... Clinical Later In Year * Influenza antigen Used Was Non-Egg-Based * True Powder ... in two animal models using the H5N1 (bird flu) antigen were required in order to proceed with a planned ... I clinical trial later this year. The bird flu antigen used in these preclinical studies was from a ...

DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program

... to FluMist, which is made of a live vaccine antigen in a liquid formulation, DelSite's nasal powder ... nasal cavity. The in-situ gel provides sustained antigen release and prolonged nasal residence, thereby increasing exposure to the antigen that results in increased immune response. ...

Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage

... a high immune response at the lowest dose of H5N1 antigen reported to date. The vaccine containing only 1.9 micrograms of antigen generated a high level of seroprotective immune ... trial, vaccine containing 3.75 micrograms of antigen generated a high level of seroprotective immune ...

PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009

... SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation rPA anthrax vaccine ... exposure to chemical nerve agents RypVax(TM) -- a recombinant dual antigen vaccine for plague For more information about PharmAthene, ...

ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens

... to exclusively license seven cancer antigens from Immunotope Inc., an antigen discovery company. These proprietary antigens specifically target breast, ... within a robust clinical trial program." "This agreement combines our antigen discovery expertise with IVT's product development capabilities and we are ...

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth

... potent anti-tumor activity of a BiTE antibody binding to carcinoembryonic antigen (CEA) and to CD3 on T cells. Micromet and MedImmune are jointly developing ... CEA, also called CD66e or CEACAM5, was selected as target antigen for development of a new BiTE antibody program because CEA is widely ...

PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009

... SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation rPA anthrax vaccine ... exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about ...

OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China

... the last two years, OriGene also has developed a genome wide collection of antigen standards and over 100,000 tissue samples that are ideal tools for high ... a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. ...

PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel

... -- SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine ... to chemical nerve agents -- RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please ...

PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008

... include: -- SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- ... exposure to chemical nerve agents -- RypVax(TM) -- a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit ...

PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference

... include: -- SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- ... exposure to chemical nerve agents -- RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit ...

PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases

... include: -- SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- ... exposure to chemical nerve agents -- RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit ...

PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008

... include: -- SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- ... exposure to chemical nerve agents -- RypVax(TM) - a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit ...
Other Contents
(Date:7/11/2014)... at the National Institute of Standards and Technology ... work more effectively, they often prove that necessity ... the case recently for M. Lorna De Leoz ... growing specialization of glycomics. Glycomics is the study ... that are attached to proteins and lipids and ...
(Date:7/11/2014)... July 3, 2014, Shenzhen, China Researchers from Salk ... for the first time evaluated the safety and ... and successfully developed a new method, TALEN-HDAdV, which ... pluripotent stem cell (hiPSC). This study published online ... important theoretical foundation for stem cell-based gene therapy. ...
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2A first direct glimpse of photosynthesis in action 2
(Date:7/12/2014)... Beach, FL (PRWEB) July 12, 2014 ... of high-quality peptides that are used solely in scientific ... honor two successful years in business, Maxim Peptide, which ... has just launched a new and updated website that ... research blog section has been updated with fascinating articles ...
(Date:7/11/2014)... Recently, DressyQuinceanera.com, a well-known wedding dress manufacturer ... to its online category. Furthermore, the firm has ... discounted rates, up to 62% off. , The brand ... in terms of quality and style. All items in ... also offered for the company’s other items: lace evening ...
(Date:7/11/2014)... July 11, 2014 As transvaginal ... against Johnson & Johnson’s Ethicon Inc. unit continue ... notes that the Texas Attorney General’s Office has ... of surgical mesh products used to treat pelvic ... a report from kens5.com, the probe began nearly ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July ... HIV who was thought to be cured by immediate and ... levels of the AIDS-causing virus in her bloodstream, disappointed federal ... years old, had remained virus-free even though she stopped taking ... hoped her remission would open the door to a functional ...
(Date:7/11/2014)... 2014 The report, “Specialty Synthetic ... & Geography - 2018,” defines and segments the ... an analysis and forecast of the volumes and ... (Para aramids, meta aramids, UHMW Polyethylene, carbon fiber, ... fiber, PBI fiber, PBO fiber, and liquid crystal ...
Breaking Medicine News(10 mins):Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4
Other TagsOther Tags